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Development and 
characterization of cold- 
adapted viruses for use as 
l ive virus v a c c i n e s  
H . E  Maassab and Dan C. DeBorde 
Representative viruses f rom twelve R N A  and two D N A  
virus genera have been successfully adapted to growth at 
sub-optimal temperature (cold-adapted). In almost every 
case there was a correlation between acquisition o f  the 
cold-adaptation phenotype and loss o f  virulence in the 
normal host whether animal or marl Overall the best 
method o f  cold adaptation to develop a live virus vaccine 
line appeared to be a stepwise lowering o f  the growth 
temperature allowing time f o r  multiple lesions to occur 
and~or be selected. In addition, the starting virus should 
be a recent isolate not as ye t  adapted to a tissue culture 
host and the cold-adaptation process should then occur in 
a host heterologous to the virus' normal host These 
viruses have been reviewed in the light o f  their cold- 
adaptation method and successful production o f  an 
attenuated line as virus vaccine candidate Finally, 
detailed information is presented fo r  the cold-adaptation 
process in influenza virux 
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Introduction 
Virulence of a virus, a variable characteristic under 
polygenic controL is influenced by the virus strain, the 
host, or both these things. A review of the literature 
provides numerous examples of factors modifying 
virulence, some classified as host factors, while others are 
considered as viral in origin. In the interactions of the 
virus with its host celk both entities play an important role 
in the determination of the outcome which is a measure of 
the virulence of the virus. The host factors affecting 
manifestation of virulence and also influencing the 
outcome of host-virus interactions are determined by the 
genetic constitution and also the physiologic state of the 
host cells. Systemic factors both specific such as immunity 
of the host as well as non-specific, such as hormones, 
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nutrition and age can also influence the consequences of 
exposing a host to virus. The properties of a virus that are 
important determinants of virulence are: quality, e.g. 
inactive or defective virus competes for cell receptor in the 
initiation of infection, the quantity or the dose of the virus 
and its genetic constitution. The mechanisms in the 
expression of virulence are also influenced by viruses that 
are poor inducers of interferon and those which tend to be 
resistant to interferon by their ability to spread and to 
exhibit a high rate of multiplication in the host cell. An 
additional property that also affects the course of 
infection is host temperature. In vivo observations have 
demonstrated that high temperature plays a defensive role 
and can suppress viral replication and limit spread whilst 
lower temperature allows a higher rate of viral replication 
and more severe expression of a disease. 
The role of temperature in microbial disease has been 
the subject of numerous reports in the literature, a high 
normal body temperature in certain species of animals 
being found to play a defensive role in immunity to 
infectionL Enders and Shaffer ~ presented definitive 
evidence that the capacity of Pneumococcus III to 
multiply at41°C was a genetic property and thus gave the 
first hint of the effect of temperatures on virulence of 
different strains of the same microbe. In general, it was 
stated that hyperthermia has no effect on highly virulent 
strains, whereas it has a marked effect on strains with low 
virulence, BurneP in 1936 demonstrated that an animal 
virus such as influenza produced lesions and death of 
eggs incubated at 36°C but not at 39°C. The studies in 
animals, although qualitative and sometimes speculative 
in nature, have not offered any more insight into the mode 
of action: it is not clear whether the mechanism involves 
changes in the host or whether it affects the virus 
directly. 
In vitro studies have shown that temperature alters viral 
development in tissue culture infected cells. Correlation 
was found between virulence and the ability of virulent 
strains to grow at temperatures above physiological range 
(~40°C).  From all points of view, virulence can be 
quantified and it is a quality that can be added to or lost 
experimentally from a virus strain. 
In recent years, emphasis has been placed on 
development of techniques for quantification of the events 
0264-410X/85/050355-15 $03.00 
© 1985 Butterworth 6" Co. (Publishers) Ltd Vaccine, Vol. 3, December 1985 355 
Cold-adapted live virus vaccines" H.F. Maassab and/3. C DeBorde 
that underlie the basis of virulence and on attempts to 
define molecular aspects of virus replication. One 
approach has been the development of thermo-sensitive 
lines of virus using chemical mutagens. Temperature 
sensitive mutants (ts) have permitted, in some instances, 
the definition of the number of genes in virus genomes 
and their function. The acquisition of ts lesions 
apparently caused a decrease in virulence. In the field of 
practical virology, the isolation of these mutants has 
provided the opportunity for their use as attenuated live 
vaccine strains. The development and use of conditional- 
lethal mutants of animal viruses has been the subject of 
two elegant reviews by Fenner 4 and more recently by 
Ghendon 5. 
Characterization of cold-adapted mammalia 
viruses 
In general, cold adaptation requires serial or step-wise 
passages at reduced temperatures for the derivation of 
Table 1 Cold-adapted mutants of animal viruses 
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African horse sickness 
Genus Orthomyxovirus 
Influenza type A 
Influenza type A 
Influenza type B 
Genus Morbil l iv irus 
Measles 
Genus Paramyxovirus 
Parainfluenza type 1 
Parainfluenza type 1 




















Passage at 25°C 
Stepwise passage at 35°C(5), 33°C(5), 
30°C(5), 27°C(5), and 24°C(5) 
Stepwise passage at 33°C(9), 30°C(9), 
27°C(8), 25°C(21) 
Passage at low temperatures 
Passage at 37°C and 24°C 
Passage at 30°C(13) 
Passage at 23°C(15) of the adapted 
virus, above 
Stepwise passage at 25°C(10), 23°C(5) 
Stepwise passage at 30°C, 27°C, and 25°C 
Stepwise passage at 33°C(7), 30°C(10), 
and 25°C(20) 
Stepwise passage at 35°C(5), 30°C(3), 
28°C(3), 26°C(18) 
Passage at 30°C(25) 
Passage at 25°C(17) 
Stepwise passage at low temperatures 
Passage at 26-28°C(45) 
Stepwise passage at 36°C(60), 33°C(10), 
30°C(10), 27°C(10), 25°C(10) 
Stepwise passage at 33°C(1 ), 30°C(4), 
27°C(2), 25°C(2) 
Stepwise passage to 33-25°C 
Passage at 26°C(20) 
Passage at 25°C 
Stepwise passage at 33.5°C(3), 22°C(10), 
20°C(35) 
Stepwise passage at 34°C(21 ), 
28°C(12), 26°C(19) 
Passage at 25°C 
Passage at 32°C 
Passage at low temperature 
Passage at 23°C 
Passage at 30°C(9) 
Passage at low temperatures 
Passage at 25°C(1 O) 
Passage at 30°C, 22°C 
Stepwise passage at 30°C(10), 29°C(4), 
27°C(1 ), 125°C(5) 
Kitsak 66 
Rohitayodhin 13.67 and Hammon 
Yoshida et al. TM 
Wittman and Ahl 7° 
Urvantesev eta/. TM 
Dubes and Chapin 6 
Dubes and Wenner 7 
Koprowski eta/. 9 
Lwoff 8 
Sabin 1 
Gevaudan et al. 12 
Jablonsk? 1 
Brayton and Maassab 15 
Mirchamsky and Taslimi 72 
Aleksandrova 28.78 and Smorodintsev 29 
Maassab 30 
Maassab 73 
Hozinski et al. 74 
Potash et al. 16 
Maassab, unpublished data 
Belshe and Hisson TM 
Friedewald et aL 19 
Maassab, unpublished data 
van der Heide 75 
Selimov and Nikitina 22 
Clark and Witkor 21 
Flamand 23 
Yurlova eta/ .  76 
Maassab and McFarland 24 Huang et aL 25 
Fidzianska 77 
Kirn and Braunwald 26 
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attenuated cold variants containing multiple lesions in 
their genomes. Cold adaptation of animal  viruses is 
generally accompanied by loss of  virulence and the 
appearance of various distinctive markers which may 
vary with the virus and host system. The biological 
attributes that are generally acquired by viruses when 
adapted to grow at low temperatures are reduction of 
virulence and reduced plaquing efficiency at high 
temperatures. These markers, plus various others which 
are more variable in occurrence (restriction of growth in 
certain host cells, temperature stability, sensitivity to low 
pH, and plaque size) can be used to differentiate the cold- 
adapted strains from their progenitors. Table 1 represents 
a summary  of the cold-adapted animal viruses that have 
been produced and the procedure followed for their 
development. 
The attenuation of  animal viruses for use as live 
vaccines has been achieved by: (1) serial passage of virus 
in heterologous hosts; (2) repeated serial passages in a 
single host; and (3) adaptation of the virus to grow at 
suboptimal temperature ~. 
Adaptation of viruses to grow at lower temperatures 
(usually 25 ° C) using diverse techniques will be the central 
theme of this section for development and character- 
ization of live attenuated virus vaccines intended for 
human use. The following aspects of  cold adaptation of 
animal viruses will be considered: (1) the procedure and 
criteria used to select adapted strains: (2) quantification 
and characterization of the cold adapted strains: (3) 
methods used to evaluate in vitro and in vivo loss of 
virulence: (4) presence of markers: (5) genetic stability and 
(6) behaviour and acceptability as live virus vaccine 
candidates. Studies of cold-adapted animal viruses other 
than influenza viruses, and studies of attenuation of 
influenza virus by cold adaptation for use as live virus 
vaccines in man will be covered. For some of the early 
work on animal  viruses listed in Table 1 detailed 
biological analysis with quantitative data are not 
available. This section will include summary  data only for 
those viruses which have a sufficient body of information 
to allow interpretation of the relationship between cold 
adaptation and loss of  virulence, 
E n  t e r o v i r u s  
Early work on cold adaptation was performed on the three 
types of  poliovirus at 23-30°C by several groups ~,6-~°. 
These groups were able to demonstrate that gradual 
lowering of the temperature during serial propagation of 
the viruses resulted in the derivation of cold mutants, 
showing increased reproductive capacity of  growth at low 
temperature (rct/25°C+) and decreased infectivity at 
higher temperatures (rct/40°C--). The cold mutants were 
less virulent when inoculated intraspinally in rhesus and 
cynomulgus monkeys. Characteristics of those cold 
mutants included small plaque size at higher tempera- 
tures and larger plaque size at lower temperatures. 
Sensitivity to low bicarbonate or low pH resulted in lower 
plating efficiency. Variation did not exist in growth 
properties within the set of  cold mutants or within the set 
of their progenitors upon growth at differing temperatures 
and also in the degree of attenuation to the subhuman 
primates. For high yielding cold mutants of  three types of  
polio, plaque-purification was accomplished and genetic 
stability demonstrated and attenuation documented for 
their use as live virus vaccines. 
A cold mutant  of  Echo 9 was developed by Jablonski 11 
through passages of  lower temperature 25 or 30°C. 
Lowering the temperature of  incubation of infected cells 
resulted in the derivation of a mutant  with altered 
biological properties. The mutant  exhibited the rc t /40-  (T 
marker) characteristic and also slight antigenic changes 
when compared to the prototype strain. The kinetics of  
growth at different temperatures was host-dependent, 
with variations in infectious titres apparent between the 
strains. Since the original viral preparation was not 
cloned, a conclusion concerning whether selection or 
spontaneous mutation can explain the emergence of the 
mutant is not possible. Data on the alteration of virulence 
of the mutant  during adaptation were not furnished. 
A third virus of the Picornaviridae family, coxsackie 
B5, was adapted to growth at low temperature ~z. A cloned 
preparation of coxsackie B5 has undergone progressive 
adaptation to lower temperatures starting with a 36°C 
incubation and ending with a 26°C incubation. The 'cold' 
mutant was plaque-purified at 26°C prior to character- 
ization in vitro and in vivo. Comparison of the cold variant 
to the original strain has shown the acquisition of the 
temperature-sensitive marker  in the "cold" line. Decreased 
virulence to suckling mice of the cold-adapted strain upon 
intracerebral inoculation was also shown. Thus, 
adaptation of coxsackie B5 to growth at low temperature 
was correlated with attenuation. 
F l a v i v i r u s  
Attenuated strains of Japanese encephalitis (JE) virus 
have been produced through cold adaptation by two 
different laboratories. Rohitayodhin and H a m m o n  n tried 
to attenuate two different strains of Japanese B 
encephalitis (JBE) virus by adaptation to growth in 
hamster kidney cell (HKC) tissue culture at suboptimal 
temperatures. One strain was the mouse-adapted 
Nakayama virus in its 47th mouse passage. The other was 
a mosquito isolate designated Okayama Culex trita- 
eniorhynchus-541 (OCT-541). The Nakayama virus 
failed to show any significant change in mouse virulence, 
which the authors intepreted to mean that its extensive 
growth in mice had removed any mouse-attenuated virus 
particles prior to their own selection procedures. 
OCT-541, however, did show a significant change in 
mouse virulence when administered subcutaneously (s,c.). 
This virus was cold adapted by several different methods. 
Two lines were grown directly at the low temperatures of  
27 and24°C, and two lines were stepwise adapted to a final 
temperature of  24°C, one with one passage at each 
intermediate temperature and one with five passages at 
each intermediate temperature (see Table 1). All these 
lines showed a drop of one to two log units in LDs0 titres 
when given intracerebrally (i,c.) in suckling mice, and the 
average survival times were seen to increase from 6 to 12 
days. The virus adapted by five passages at each 
intermediate temperature (line 35-24) proved to possess 
the most stable attenuated characteristics, and was chosen 
as the virus to use in further experiments. Because this 
disease follows a mosquito-swine cycle, it was also 
desirable to test the attenuated virus in mosquitoes. 
Unlike the original unadapted OCT-541 strain, the cold- 
adapted line 35-24 failed to infect the mosquitoes and n o  
transmission could be demonstrated. The only problem 
with line 35-24 for use as a live virus vaccine is that the 
mice demonstrated no production of neutralizing 
antibody after being infected with the attenuated virus, 
and these mice showed no immunity to subsequent wild 
type virus challenge. 
Later work ~4 used a virus isolated from the brain ofa  JE 
patient who died in Osaka Prefecture in 1966. While these 
researchers also used a stepwise cold-adaptation method, 
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their experiments were expanded in the number of 
markers examined at each stage of cold adaptation and 
the tissue culture system used was monkey kidney cells. 
Once a cold variant was achieved which had the desired 
attenuation and immunogenicity it was further adapted to 
growth at 33°C in quail embryo fibroblasts for better 
efficiency of virus growth for vaccine production. Virus 
lines were tested for virulence in 5 g mice and in suckling 
mice, both i.c. and s.c.; production of viraemia in one 
month old piglets; infection rate in CT mosquitoes; and 
finally neurovirulence in monkeys. After primary adapta- 
tion in monkey kidney cells at 37°C for 68 passages, the 
virus had already lost its capacity to cause viraemia in one 
month old piglets. This ability never returned. Alter 
adaptation to 33°C it could no longer cause disease in 5 g 
mice s.c., and finally over the course of 21 passages at 25°C 
the virus showed; (1) lower virulence on i.c. injection into 5 
g mice; (2) a higher i.c./s.c, ratio of LDs0 titres in suckling 
mice; (3) very low infectivity in CT mosquitoes; and (4) no 
encephalitis upon Lc. injection into monkeys. All markers 
were retained after growth on quail embryo fibroblasts at 
30°C. In addition, all markers of attenuation remained 
stable after passage in suckling mouse brain or alter 
infection in one day old chicks. Protection experiments in 
one week old or in one month old piglets showed no virus 
disease due to vaccine, and piglets were resistant to 
challenge with 8.5 logs of infectious virus (100 times the 
maximal amount of virus contained in a whole mosquito). 
Pregnant sows given this live virus vaccine showed no 
disease and delivered normally. No vaccine virus was 
isolated from the new-born piglets. The use of multiple 
markers for screening and the stepwise method of 
adaptation ensured the production of a stable, attenuated 
JE line for use as a live virus vaccine. 
Arenavirus 
A cold adapted non-virulent variant of the Armstrong 
strain of lymphocytic choriomeningitis virus(LCMV) was 
isolated after 17 passages at 25°C in L929 cells ~5. Virus 
from passage 17 (P17) did not cause death in mice 
inoculated i.c. with up to 2000 p.f.u. This titre 
represented 1000 LDso of the parental LCMV. Both the 
wt LCMV or the ca PI7 virus could be isolated in 
essentially equal amounts from the brains of i.c. 
inoculated mice. When the brains were compared 
histopathologically, no histological changes were seen in 
PIT virus-infected brains, while the wt LCMV produced 
evidence of meningitis as early as four days post-infection. 
No neutralizing antibody and only low levels of com- 
plement fixing antibody were detected after infection with 
PI7 virus. These mice were protected to challenge with 
100 LDs0 of parental LCMV, however. PI7 was passaged 
three times through the mice by i.e. inoculation and the 
final isolate retained the same biological characteristics of 
the initial Pl7 virus. Thus the biological changes in the 
PI7 virus were quite stable. 
Paraml~xovirus 
Parainfluenza virus type 1 was serially passaged 20 
times at 26°C in primary African green monkey kidney 
(AGMK) tissue culture followed by three terminal- 
dilution purifications ~6. After these last three passages the 
existence of a ts mutant became apparent. This mutant 
grew poorly at 38 or 39°C in tissue culture and also grew 
poorly in the trachea and lungs of hamsters. The mutant 
was able to induce almost complete resistance to 
subsequent replication ofwt virus in the lower respiratory 
tract of inoculated animals for at least two months. While 
the procedures used in this paper are typical for the 
production of a cold adapted variant, the results in this 
case are difficult to interpret because the starting wt 
parainfluenza type 1 virus grew as well or better at 26°C 
than it did at 35°C or 37 ° C. In addition, the appearance of 
the ts mutant occurred after the three terminal-dilution 
passages, but not before, thus the growth at 26°C may not 
have played a significant role in the selection of this 
variant 
Frickey ~7 attenuated type 3 parainfluenza virus that 
had been previously passaged in cercopithecus monkey 
kidney (CMK) tissue culture 45 times at 37°C, by one 
passage in CMK cells at 28°C, followed by 18 passages at 
25°C (the fourth through the eighth passage at 25°C were 
made using terminal-dilution techniques). The viruses 
examined were the parental virus, 25°C passage-3, and 
25°C passage-12. Both 25°C passaged viruses grew equally 
well at 25 or 37°C, while the parental virus grew 100-fold 
less at 25°C than at 37°C. The plaque sizes of both cold- 
adapted viruses were significantly larger than those of the 
parental virus. Pathogenicity of the parental virus and of 
the 12th passage at 25 ° C cold- adapted v{rus was compared 
in the lungs of 58-day-old hamsters. Both viruses 
multiplied rapidly in the lungs on day one. Cold adapted 
virus titre began to decline after day one, while the 
parental virus reached its maximum titre on day three. 
The drop in cold-adapted virus in the lungs of these 
animals was associated with the early appearance of 
interferon at days one and two. Equivalent titres of inter- 
feron did not appear in the lungs of wt virus-infected 
hamsters until days four and five. Finally, both wt and 
cold-adapted viruses produced equal rises in circulating 
HAI antibodies detectable at days six and seven alter 
inoculation. 
Belshe and Hissom ~8 serially passaged the JS strain of 
parainfluenza type 3 virus three times at 33.5°C, tbllowed 
by 10 passages at 22°C, and finally by 35 passages at 20°C. 
Clones were plaque-purified in AGMK cells from 
passages 7, 12, 18, and 45. At each of these stages the 
percentage ofts mutations in the population increased: 1 
of 9 for passage-7; 3 of 12 for passage-12: 80% for passage- 
18: and 100% for passage-45. Each ts chine also demon- 
strated a tiny plaque (tp) phenotype. Tp was defined 
as plaques which were 50% or less of the wt plaque size. 
Each ts clone was ca, but not every ca clone was ts. A 
selected clone from each of the above lbur passages was 
further characterized for pathogenicity in weanling 
hamsters (Hissom and Belshe, personal communication). 
All four clones were ca, ts and tp. A fifth clone isolated at 
the 18th passage which was only ca (non ts and non tp) 
was also examined. This clone and the clone isolated at 
the 45th passage (which was ca, ts, and tp) could not he 
recovered from the hamsters" turbinates or lungs.The other 
ca clones grew less in the lungs than in the turbinates - -  
not a property of the wt virus. All cold variants were 
genetically stable in the hamsters except lk~r the virus 
isolated at the 7th passage. This partially revertant virus 
isolated from the nasal turbinate produced small, 
indistinct plaques at 37 ° C, with a 100-fold decrease in titre 
at 32°C. This latter study, unlike the first two, benefited 
from a plaquing method by which the cold variant viruses 
could be analysed and titrated. 
St-udies in our laboratory have adapted recent hum~/n 
isolates of parainfluenza type 1 and 3 viruses to grow in 
primary chick embyro kidney (PCEK) cells at 35°C and 
these viruses produced CPE and hence could be plaque- 
purified. Table 2 presents the tissue culture growth 
characteristics for a cold adapted type 1 virus after 10 
consecutive passages at 25°C. Similar work is in progress 
with ca-para-3. 
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Table 2 Infectivity titre of a cold-adapted human para-1 
(ca-para- 1 ) 
Figure I Diagrammatic illustration of the derivation of respiratory 
synctial (RS) virus cold variant 
25°C 33°C 35°C 39°C Markers 
wt-para-1 no plaque 2 x105 3 x105 1 x104 wt 
ct-para-1 3 x 1 0  3 5 x 10 5 2 x 10 5 np ca; ts 
np, no plaques 
Pneumovirus  
Respiratory syncytial virus (RSV) was cold adapted by 
21 passages in bovine embryonic kidney culture (BEK) at 
34°C, followed by 12 serial passages at 28°C ~9. This virus 
was terminally diluted three times at 28°C and then 
passaged 16 times at 26°C. Virus from the 21st, 33rd, and 
52nd passage levels was isolated and used for volunteer 
studies in man. The virus was inoculated intranasally, and 
was shown to be less infectious and less virulent for man 
than the wt virus. Virus was plaqued in BEK cells at 28 and 
37°C. Cold-adapted virus gave 37/28°C titre ratios ranging 
from 0.04 to 0.4, while wt virus gave values ranging from 
1.4 to 6.2. Growth of virus at 28°C as opposed to 26°C did 
not select for an attenuated virus. Further studies with this 
ca RSV in infants and in children 2° indicated that the 
virus retained a low level of virulence for individuals 
undergoing primary infection. Children older than eight 
months were asymptomatic during infections with this 
line but did not show local and systemic immune 
responses. It is possible that a more attenuated and 
temperature-sensitive virus could be isolated if lower 
temperatures of 24 or 20°C had been used, as was the case 
for paramyxovirus type 3 ~8. 
A diagramatic illustration of the derivation of cold 
adapted RSV made in our laboratory is presented in 
Figurel. Clone 14 of the cold-adapted RSV was compared 
to wt RSV in the ferret animal model system. The results 
are shown in Table3. The cold-adapted RSV did not grow 
in the lungs, unlike the wt RSV, and thus was attenuated 
for ferret. Intranasal administration of clone 14 to 
chimpanzees showed a moderate degree of reactogenicity 
(Chanock, personal communication). However, the ca 
RS virus isolated in Wt-38 at 35°C 
Three serial passages at 25°C 
(Each passage was incubated for 1 2odays) 
Focal cellular degeheration at 25 C 
(the foci picked and passed) 
Plaque titration 
Three plaque purificatidns in Wl -38  at 25°C / 
Virus pool of various plaques~made in Wl -38  for biological 
characterization 
line used was not adequately plaque-purified. The 
isolated virus also retained its ca and ts markers providing 
evidence for its phenotypic stability. 
Rhabdovirus 
Among other rct/40.5-rabies virus strains, Clark and 
Wiktor ~1 examined two substrains of challenge-virus- 
standard (CVS) cultivated at 23-25°C. Among all the 
strains examined, there was no consistent correlation 
between attenuation after intracerebral injection in 
weanling or newborn mice and temperature sensitivity. By 
the 50th passage in BHK-21 cells, both cold-adapted virus 
strains were rct/40.5--, but neither showed significant 
attenuation for mice. Attenuated strains of CVS were 
produced by serial passages in either the viper cell line, 
VSW, or in the lizard cell line, GLI, and these, likewise, 
showed no correlation between rct/40.5-- and attenuation. 
Selimov and Nikitina 22 had reported ~complete cor- 
relation" between the degree of temperature sensitivity and 
attenuation of the SAD strain of fixed rabies virus. The 
discrepancy between these two reports has not been 
resolved, although Clark and Witkor" found the lack of 
correlation between rct/40.5-- and attenuation to be 
reasonable since 
"'fever is a late expression of rabies-virus infection", 
and that 
Table 3 Series I, ferret response to the wild type RS virus 
Infectivity titre TCID5o ml m at 
25°C 33°C 39°C Marker 
Time postinfection (days) 
T L T L T L 
1 <1.0 <1 .O 3.0 2.0 2.3 1.5 wt  
3 <1.0 <1.0 3.5 3.5 3.0 3.3 wt  
5 <1 .O <1.0 4.0 4.0 4.3 3.5 wt 
9 <1.0 <1.0 4.3 4.O 3.5 3.0 wt 
Series II, ferret response to clone 1 4, ca - RS virus 
Infectivity titre TCID50 m1-1 at 
Time postinfection (days) 
25°C 33°C 39°C Marker 
T L T L T L 
1 1.5 1.0 2.5 1.5 <1.0 <1.0 ts, ca 
3 2.5 1.0 3.5 1.5 <1.0 <1.0 ts, ca 
5 3.0 <1 .O 4.3 1 .O <1.0 <1.0 ts, ca 
9 2.0 <1 .O 3.0 1.0 <1.0 <1.0 ts, ca 
T, turbinates; L, lungs 
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"the fatal outcome of the infection may only be aborted 
at a very early stage, long before the development of 
fever". 
Experiments with a second Rhabdovirus, vesicular 
stomatitis virus, by Flamand 23 supported the findings of 
Clark and Witkor al in that nine successive passages at 
30°C in chick embryo fibroblasts caused no apparent 
genetic effects in the virus. The Rhabdovirus genus 
appears to be the only virus group examined that does not 
generally link cold adaptation and attenuation. One 
reason may be that the starting viruses have already been 
highly adapted for a particular system, as the fixed CVS 
rabies line. Rohitayodhin and Hammon"  were unable to 
attenuate a mouse-adapted strain of Japanese B 
encephalitis virus, but had no problem doing so with a 
new mosquito isolate. 
H e r p e s v i r u s  
Herpes simplex virus type 1 (VR3 strain) and type 2 
(MS strain) were cold-adapted at 25°C by serial passages 
in primary chick kidney cells (PCKC) using both liquid 
overlay and plaquing by Maassab and McFarland 24. Both 
cold-adapted type 1 and type2 viruses grew equally well at 
either 25 or 35°C but were temperature-sensitive at 40°C. 
The cold-adapted type 1 virus grew4 log units less at 40°C 
than it did at 25°C, and the cold-adapted type 2 virus 
produced no plaques at all at 40°C. Both original strains 
grew equally well at 35 or40 ° C, but not at all at 25 ° C. Both 
cold adapted viruses were shown to be attenuated for mice 
when inoculated i.c. The cold adapted type 1 virus had a 
I(P 3 p.f.u./LDs0 as compared to 16 p.f.u./LDs0 for the wt 
type 1 virus. The cold adapted type2 virus showed an even 
more striking loss of virulence. It had a >1062 p.f.u./LDs0 
as compared to 3 p.f.u./LD50 for the original type 2 virus. 
Mice which had been inoculated with the cold adapted 
herpes simplex type 2 virus were shown to be protected 
against i.c. challenge by 100 MLD50 of the virulent parent 
virus. Histopathological studies by Huang et aZ 25 of mice 
brain tissue and trigeminal ganglia after i.c. inoculation 
with either the herpes simplex type 2 parental strain or its 
cold adapted derivative revealed significant differences in 
their pathological processes. The wild-type virus caused 
severe meningitis and necrotic lesions by seven days post- 
inoculation, while the cold adapted virus caused only a 
mild meningitis and no necrotic lesions. Data suggested 
that the cold variant virus was unable to lyse its host cell 
the neuron, and thus did not spread and continue the 
infection. The cold mutant of herpes simplex virus type 2 
was able to establish a latent state and to persist in the 
host. The cold variant offers an excellent model system 
which can be used to study latency and the interaction 
between host cell and virus, and might give an insight into 
the mechanisms of naturally occurring HSV infection. 
Thus, cold selection of a DNA virus yielded a variant 
population which was temperature sensitive, and due to 
its restricted ability to grow and spread in vivo was 
avirulent for mice. 
P o x v i r u s  
Kirn and Braunwald 26 cold-adapted the mouse viru- 
lent WR vaccinia virus strain by stepwise passages from 37 
to 25 ° C (see Table 1 ). The 25°C variant gave larger plaques 
than the parental type and was also more sensitive to 
temperature effects. The cold variant showed complete 
loss of virulence when administered i,c. in mice, and was 
less virulent than the wt in rabbit. Two cold variants of 
vaccinia virus were made and characterized by 
Fidzianska =7. The parental virus was the rabbit skin 
grown Lister strain, passed twice on chorioallantoic 
membranes (CAM) of chick embryos and labelled Lister- 
C1. The cold variant Lister-30 was derived from Lister-C1 
by three passages on CAM at 30°C. Lister-22 was derived 
from Lister-30 by two passages at 22°C in chick embryo 
cells (CEC), one passage at 37°C in CEC, 12 passages at 
22°C in African Green monkey kidney(AGMK) cells, and 
finally three passages in CAM at 29°C. Both viruses 
resembled the Lister-C1 virus in pock type(opaque, white) 
although half as large, and all three had the same plaque 
type (distinct, clear) though the cold variants were ~ 1.5 
times larger than Lister-C1. Lister-30 and Lister 22 both 
had reduced virulence in mice. Lister-30 was intermediate 
in virulence between Lister-C1 and Lister-22. Lister-22 
infected mice showed no mortality, while Lister-30 gave 
42.8% mortality, and Lister-C1 gave 85.7% mortality. 
Lister-22 was reduced in infective titre by 3.0 log units at 
42°C. Thus for vaccinia virus, cold adaptation is 
accompanied by attenuation, moderate temperature 
sensitivity, and increased plaque size. 
Development of cold adapted virus 
Type  A i n f l u e n z a  v irus  
Devising means to control epidemic influenza virus is 
a challenging problem that has resulted in collaborative 
research efforts for the development of attenuated live 
influenza virus vaccine. It is recognized that im- 
munization with live virus may offer many practical and 
theoretical advantages over immunization with in- 
activated vaccine. Although various methods have been 
used in the development of live virus vaccine, the 
adaptation of the virus to grow at suboptimal temperature 
(25°C) has been the most useful approach in terms of 
genetic stability. 
Influenza viruses have been cold-adapted by several 
groups 2s-~'Ts. The studies have relied upon pressure 
selection of a variant which favours growth at 25°C, or 
upon chance mutation resulting in a low temperature 
variant with reduced virulence. The variants derived in 
some instances did not exhibit optimum growth at 25°C. 
In our experience, the simple criteria of in vitro growth at 
25°C concomitant with a decreased virus yield at 
supraoptimal temperatures, i.e. >38°C, were not accept- 
able criteria to guarantee delivery of an attenuated virus 32. 
It appears that in order to achieve the desired attenuation 
by cold adaptation, an influenza virus should undergo 
step-wise or gradual lowering of incubation temperature 
in primary chick kidney (PCK) cells. This process helps 
ensure that the selected virus has multiple lesions in its 
genome resulting in a genetically stable, attenuated cold- 
adapted variant. The presence of multiple lesisons that 
provide the vaccine with genetic stability fits perfectly with 
the concept of virulence being polygenic. In addition to a 
step-wise cold adaptation procedure, the passage level 
and the host in which it was grown seem to influence the 
cold adaptation process. For instance, freshly isolated 
strains at 36°C can be adapted to growth at 25°C with 
fewer cultural manipulations than isolates which have 
been passaged for some time prior to cold adaptation. It is 
also true that strains isolated in PCK cells require fewer 
passages at 25°C for expression of optimal growth than 
strains originally isolated in embryonated eggs. 
The initial work of adapting influenza virus to grow at 
25°C was done using a mouse-adapted, virulent line of A/ 
AA/6/60 virus and comparing the loss of virulence to the 
degree of cold adaptation 3°. The results demonstrated that 
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Table 4 Passage history of cold variant A / A A / 6 / 6 0  (H3N2), 








Isolation in PCK cell cultures at 36°C 
Passage in PCK at 36°C 
Serial passage in PCK at 33°C 
Serial passage in PCK at 30°C 
Serial passage in PCK at 25°C 
Serial cloning by plaque passages in PCK at 
25°C 
E-1-3 Serial passage in SPAFAS embryonated hens' eggs 
at 25°C 
Table 5 Markers used to differentiate the cold variant of type A 
influenza virus from the original strain 
Markers Cold variant Original strain 
pH Sensitivity to low pH Grow equally well at 
low and neutral pH 
Grow equally well at 
36 and 41 °C 




Plaque size and 
shape at 36°C 
Plaque size and 
shape at 25°C 
Inability to grow at 
41 °C 
Small (<3 mm) 
irregular boundary 
Average size 
(3-4 mm) irregular 
boundary 
the emergence of a cold variant was correlated with loss of 
virulence when the virus was administered intranasally to 
mice. The cold-adapted line seemed to grow and infect 
mice without signs of disease and to elicit protective 
antibody response a3. Since the passage history of the 
mouse-adapted line was not acceptable as a vaccine 
candidate, selection of a cold-adapted mutant with a 
proven history was accomplished. The Asian strain A/ 
AA/6/60 (H2N2) was isolated directly from a throat 
washing into SPAFAS-derived PCK cells incubated at 
37°C. The process of growing the virus by gradually 
lowering the temperature of incubation was then 
undertaken, A gradual lowering of the incubation 
temperature rather than a sudden sharp decrease was 
essential for optimal growth. The data seem to indicate 
that the infectious yield of virus from the initial passage at 
each particular temperature, starting with 36°C and 
proceeding through 33, 30, 27, to 25°C was 2-3 log units 
lower than the 10th and final passage at the corresponding 
temperature when the infectious yield was maximal. No 
change in the titre of the virus was observed upon further 
passages and no additional benefits were derived upon 
further lowering of the incubation temperature. The cold 
variant that was adapted to grow at 25°C in PCK cells was 
then passed at 25°C in embryonated eggs with no further 
adaptation required. The passage history of the cold 
variant line is illustrated in Table4. The virus was found to 
propagate quite readily in both tissue culture and 10 day 
old embryonated eggs at 25°C with the maximal titre 
reached between the 3rd and 4th day p.i. The cold variant 
can also be propagated routinely at 33°C with a higher 
yield in a shorter period of time (48 h). Subsequently, a 
plaque assay system was developed in PCK cells in order 
to permit clone purification of cold variants for bio- 
chemical and genetic studies 34. A linear relationship 
between virus concentration and plaque number was 
found, and the specificity of the plaques was confirmed 
using-acute and convalescent serum from a clinical 
influenza illness. Differences were observed in chick cells 
infected with the original wild strain and incubated at 
25°C: there were practically no plaques found at 25°C in 
the culture infected with the original strain even upon a 
prolonged incubation of two weeks. This difference in 
plaque formation between the original strain and its cold 
variant at25°C can be used as a marker differentiating the 
two lines, and in analysing the progeny virus recovered 
after administration to experimental animals or man. 
The biological characterization of this cold mutant has 
established markers which can be used to monitor the live 
virus vaccine in the field, see Table 5. The ca line showed 
decreased infectious yield at high temperature or at acid 
pH, and gave distinctive plaque sizeaL When evaluated in 
ferrets and mice the ca Asian strain was found to be 
genetically stable, attenuated and immunogenic, and to be 
temperature sensitive with a cut off temperature of 
38°C 33'35'36. The A/AA/6/60 (H2N2) ca virus line has been 
plaque-purified seven times after the step-wise cold- 
adaptation (Table 7) and recent evidence using a 
combination of different biochemical techniques in- 
dicates the existence of mutation(s) in each of the eight 
genes of the ca line which can account for its genetic 
stability 37. Investigations into the genetic basis for the ts 
phenotype of the ca virus have been reviewed by Kendal et 
aL 3s. Additional studies are underway to correlate the ca 
and ts phenotypes to specific gene segments of the virus, 
with the preliminary evidence favouring a multigenic 
basis for the ts phenotype in the ca variant 3~,39. 
The cold adaptation method was modified for 1965, 
1966 and 1967 strains of type A influenza by using plaque- 
purified seed virus prior to adaptation. It was possible to 
adapt an Asian strain of virus to grow at25°C using fewer 
passages with only one intermediate temperature (Table 
6). The selection of a variant with optimal growth at 25°C 
was achieved with only ten passages. It is important at this 
point to stress that the number of passages required for 
successful cold adaptation varies between strains - -  it is 
not a fixed entity. The number of passages required for 
obtaining the most vigorous growth at the lower 
temperature is usually related to the previous passage 
level of the strain and the kind of host in which it was 
isolated. 
Prior to 1968, attenuation of influenza virus was 
achieved by gradually lowering the temperature of 
incubation until optimal growth of virus at 25°C was 
Table 6 Adaptation of influenza virus A / A A / 2 / 6 5 - 3 P I  a to 25°C 







aThrice plaque-purified virus prior to cold adaptation. 
bP.f.u., plaque forming units 
1 st passage 
2 x 1 0 7  
4 x 1 0 4  
1 x l 0 2  
Infectious titre-p.f.u, ml -~b 
after adaptation 
2.2 x 10 7 
4 x 1 0  6 
3 x 1 0  6 
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Table 7 Behaviour of a cold variant A / A A / 6 / 6 0  (H2N2) after a 
series of plaque purifications at 25°C 
Titre in embryonate eggs a 
No. of Serial 25°C 35°C 39°C Primary chick kidney 
plaque (p.f.u. m1-1 at 25°C) 
purifications 
1 5.3 7.3 2.5 2 x 105 
3 6.0 7.0 1.3 4 x 106 
7 7.0 7.7 1.0 5 x 10 7 
a(-Ioglo/EID5o mr  1) 
Figure 2 Flow ~agram of cold adaptation of A /A i ch i / 2 /68  
(H3N2) to 25°C 
Isolated and propagated in embryonate hens' eggs at 36°C 
1 
Series of 3 passages in PCK cells at 25°C; 
each passage was incubated for 12 days 
4th passage- few small irregular shaped plaques appeared on 
the lOth day at 25°C 
/ 
Plaque progeny passed to em~bryonate hens' eggs at 25°C 
Series of 4 passages in eggs at 25°C 
each passage incubated for 6 days 
Titre of harvest of the 4th egg passage at 25°C 
Haemagglutinati°n / " ~  EID50 a 
32 25°C 36°C 
4.0 5.7 
3 times plaque-purified at 25°C 
aEID5o is expressed as- Iog lo  EID5o m1-1 
obtained. The cold variants derived using the 1960, 1965. 
and 1967 isolates inducated high antibody levels in 
infected ferrets and mice without causing illness or 
pulmonary pathology. However, this process was a 
lengthy one, requiring six to eight months of effort before 
a stable nonpathogenic strain was available. 
A new procedure based on plaque-purification has 
shortened the process considerably. The temperature of 
incubation was changed abruptly from 36°C to 25°C and 
plaques appearing in tissue cultures held at 25°C were the 
source of virus for further passage in eggs at the low 
temperature. Figure2 is a flow diagram which follows the 
cold adaptation of A/Aichi/2/68 (H3N2) which was 
achieved in three months. The appropriate tests used for 
the Asian ca variant were applied to the Hong Kong-like 
Aichi strain and its wt counterpart. The ca line was ca and 
ts, and avirulent when tested in ferrets and human 
volunteers 33,4°,41. None of the ferrets or human volunteers 
experienced any unusual symptoms after vaccination. 
Isolates from these studies were still ts and ca, and no 
evidence of reversion to wt characteristics was found. 
With the data presented above(the experience gained over 
six years of study) and with the proven genetic stability of 
the cold variants we are able to establish rigid laboratory 
guidelines which can be followed for development of an 
acceptable, cold-adapted, live influenza virus vaccine 
without the necessity of prior testing in man. see Table 
8). 
Type B influenza virus 
The development of cold variants of type B influenza 
virus was accomplished using the same procedure 
followed for type A virus. Step-wise lowering of in- 
cubation temperature was lbllowed with certain strains in 
order to obtain cold mutants capable of growing in PCK 
cells and embryonated eggs at 25°C. Illustrative findings 
are shown in Table 9. It was found that to obtain 
maximum yields at 25°C, type B strains required fewer 
passages at the intermediate temperature than the type A 
influenza viruses. As in the case of the attenuated type A 
strains, the cold-adapted type B strains exhibited similar 
Table 8 Guideline characteristics of live vaccine strain of influenza 
virus 
(1) Growth at 25°C in PCK tissue culture and embryonated eggs. 
Y i e l d -  HA = 32 or greater. Infectivity= 106.5 EID50 m1-1 or 
g re ate r 
(2) Plaque formation at 25°C in PCK tissue culture 
Infectivity titre = 2 x 106 p.f.u, m1-1 or greater 
(3) Plaque morphology at 25 and 33°C 
Size, 3 mm or greater. Shape, uniform, round 
(4) Plaque morphology at 37°C 
Size, 2 mm or less. Shape, irregular 
(5) Temperature sensitivity 
No plaques at 40°C. 5 logs or greater decrease in infectious 
titre in embryonated eggs 
(6) Acid lability 
Plaques are smaller. Decrease in infectious titre of 3-5  logs, in 
pH 5.7-6.3 
(7) No clinical symptoms in ferrets given intranasal inoculation 
(Inoculum titre 7.0 logs p.f.u, m1-1) 
High Ab response = 1:256 or greater. Resistant to challenge 
with 1000 EID5o m1-1 up to 6 months post-inoculation 
Table 9 Adaptation of strains of influenza virus type B to growth at 25°C 
Strains of type Prior passage 
B influenza history 
No. of passages at various 
temperatures required for optimal growth 
35°C 33°C 27°C 25°C Maximum infectious titre at 
25°C in p.f.u, m1-1 
B /CoV1/65  M K3-E2 
EVMd/59 MK2-E4 
B /Mass /3 /66  E5 
B / A A / 1 / 6 6  CK1 
B /Tec /1 /69  CK1 
3 4 2 2 
3 2 2 2 
3 2 2 1 
2 2 1 1 
1 (direct to) 10 
3 x 1 0 5  
4 x 1 0 5  
3 x 1 0 6  
3 x 1 0 7  
5 x l 0 7  
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genetic markers of temperature-sensitivity, sensitivity to 
acid pH, high yield at 25°C, and loss of virulence when 
administered intranasally in ferrets 42. Two lines of proven 
and accepted passage history were developed, plaque 
purified, and characterized in man for use as attenuated 
live virus vaccines. The cold variants B/Ann Arbor/I/366 
and B/Tecumseh/1/69 were plaque-purified in PCK cells 
at25°C and evaluated in man. These tests gave evidence of 
genetic stability, immunogenicity and lack of reacto- 
genicity40, 4L 
Production o f  live influenza vaccine strains by 
"cold" reassortment 
As stated previously, considerable effort has been 
directed toward the development of live attenuated 
vaccines for the prevention of influenza. These prep- 
arations have a number of advantages over the traditional 
inactivated vaccines, especially with regard to duration 
and breadth of immunity induced, and the production of 
local antibody 43-46. Preparations of such live influenza 
vaccines pose a particular problem not encountered when 
dealing with other viruses. The surface antigens of 
influenza virus change over time, and the vaccine must 
change accordingly. Thus, not only must the vaccine be 
safe and effective, but it must also be possible to produce 
predictably a new effective vaccine variant quickly in 
response to changes in the circulating viruses. 
Certain characteristics of influenza viruses can be 
transferred between different strains by genetic re- 
assortment (reviewed in Kilbourne47). It seems likely 
therefore, that under proper conditions it should be 
possible to confer, by genetic interchange, the growth 
characteristics of a previously cold-adapted attenuated 
strain to a new antigenic variant Such an accomplish- 
ment would considerably shorten the interval between 
virus isolation and delivery of a suitable seed virus for the 
production of live vaccine. 
Earlier work on the transfer of the ca markeff s has 
shown that a "cold hybrid" of influenza virus can be 
obtained in five weeks by reassortment at 25°C. The 
studies involved the cold variant A/PR8/34 and a wild 
type parent A/England/878/69 (H3N2). The cold re- 
assortant contained the haemagglutinin of the current 
Hong Kong-like parent and the neuraminidase of the 
established cold mutant. It could grow and produce 
plaques at 25°C. It was attenuated for animals (mice) and 
highly immunogenic. However, the A/PR8/34 cold 
varianL because of its dubious passage history cannot be 
used for the production of reassortants as live virus 
vaccine for man. The availability of a donor line 
developed in our laboratory and characterized as being 
suitably attenuated, genetically stable, immunogenic, with 
defined markers has enabled us to create, in a short period 
of time, a cold adapted reassortant (these lines are 
designated CR) bearing the particular contemporary 
surface antigens desired. Two lines that have been 
designated as donors of attenuated genes (master strains) 
are the type A influenza virus A/AA/6/60 (H2N2) and the 
type B influenza virus B/AA/1/66. Both cold-adapted 
lines were cloned at 25°C and have been used since 1968 
for obtaining cold reassortants for use as attenuated live 
vaccines 49-~. 
In general PCK cells are simultaneously infected at 
25°C with approximately 5 p.f.u./cell of the two viruses, i.e. 
the attenuated donor line and the wild type virus with the 
relevant surface antigen, as shown in Figure 3. The 
duration of the various manipulations from the time of co- 
infection of PCK cells until the derivation a cold-adapted 
Figure 3 Flow Diagram. Tube method for preparation and charac- 
terization of cold adapted reassortants from a wild type virus and 














Mixedly infect PCK cells in 20 tubes with equal input 
of A /AA /6 /60  cold mutant and wt parent viruses. 
Incubate at 25°C until CPE observed. (MOI = 5/p.f.u. 
for each parent) 
Harvest from each tube and repassage separately in 
PCK cells at 25°C in the presence of A /AA /6 /60  
antiserum 
Repeat Step 2 
Repeat Step 2, but omit immune serum 
Prepare egg pools for each independent reassortant 
line 
Identify HA and NA antigens for each egg pool 
Grow each separate line or reassortant in PCK cells at 
25°C under agar overlay, without immune serum. Pick 
one large well-defined plaque for each reassortant 
line 
Repeat Step 7, using virus from plaques of Step 7 
Repeat Step 7, using virus from plaques of Step 8 
Verify cold adaptation and temperature sensitivity by 
plaque titration in PCK cells at 25, 33 and 39°C 
Identify the gene constellation of each independent 
clone by appropriate electrophoresis techiques 
On the basis of the above studies, select clones with 
the desired properties for evaluation of reactogenicity 
in the ferret animal model system 
Select the clones with the desired in vivo and in vitro 
properties for the production and safety-testing of 
vaccine pools for human volunteer studies 
reassortment clone(s) with the desired properties is N5 
weeks.. The procedure employed can be relied upon to 
reproducibly yield suitable candidate vaccine strains if 
these major conditions are met: (1) vigorous growth with 
high plaquing efficiency at 25°C; and (2) temperature 
sensitivity and loss of virulence in a ferret animal model 
system. 
This procedure involves selective pressure applied to 
the production of independent, appropriately attenuated 
clones by: (1) the temperature of incubation at 25°C, at 
which the wt parent cannot replicate efficiently: and (2) 
the presence of specific antisera against the surface 
antigens of the attenuated donor strain. Thus, emergence 
of cold reassortants bearing the current haemagglutinin 
and neuraminidase of the virulent wild type parent, but 
with the growth and other characteristics of the ca master 
strain is favoured. 
The first cold reassortant developed for use as a live 
virus vaccine in man was designated as AA-CR6-H3N2. 
It was derived from a mixed infection at 25°C in PCK cells 
of the wt A/Queensland/6/72 (H3N2) with the ca donor 
line A/AA/6/60 (H2N2). This first reassortant live virus 
vaccine line was genotyped by Alan Kendal (for review see 
Kendal et al. 3s and was shown to have six internal genes of 
A/AA/6/60 and the genes coding for the two surface 
antigens of the wt epidemic strain. The CR vaccine when 
evaluated in vitro and in vivo had all the desired character- 
istics of an attenuated vaccine line: it was ca and ts, grew to 
high titre at 25 and 33°C, and was attenuated in ferrets 
with no evidence of reversion to virulence. AA-CR6- 
H3N2 was administered to human volunteers and found 
to be acceptable as a live virus vaccine strain of influenza 
virus type 'A 52. Since 1975, reassortment at 25°C has been 
used routinely to derive live virus vaccine candidates for 
use in man 42,51. The colloraborative studies with Dr 
Chanock and Dr Murphy at the National Institute of 
Allergy and Infectious Diseases, and with Dr Kendal and 
Dr Cox at the Center for Disease Control, have provided 
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Table 10 Summary evaluation in vitro a and in vivo of vaccine candidates with similar gene composition 
Histopathology d 
Vaccine line b Wild type parent Clinical signs c (ferrets) T L 
AA-CR6-H3 N2 A /Queens land /6 /72  absent 1 + 0 
AA-CR29 C1-17 A / A l a s k a / 6 / 7 7  coryza 1 day 2+  0 
AA-CR31-H3N2 C1-2 A / A l a s k a / 6 / 7 7  coryza 1 day 1 + 0 
AA-CR31 -H3  N2 C1-13 A / A l a s k a / 6 / 7 7  absent 0 0 
AA-CR33-H1 N1 C1-1 A / U S S R / 9 0 / 7 7  absent 0 0 
AA-CR35-H1 N1 C1-2 A / H K / 1 2 3 / 7 7  absent 0 0 
AA-CR37-H1 N1 C1-1 A / C a l / 1 0 / 7 8  absent 1 + 0 
AA-CR44-H3 N2 C1-6 A / B e i j i n g / 2 / 7 9  coryza 2 day 1 + 0 
AA-CR48-H3N2 C1-4 A / W a s h / 8 9 7 / 8 0  coryza 1 day 2+  0 
AA-CR51 -H  1 N 1 C1-1 A / S h a n g h a i / 3 1 / 8 0  absent 0 0 
AA-CR59-H3 N2 C1-19 A / K o r e a / 1 / 8 2  coryza 1 day 1 + 0 
aNo reversion to ts+, ca+ in PCK tissue culture was seen for any of these cold reassortants reisolated from ferrets, bThe infectious dose 
administered to ferrets intranasally ranged from 7.7 to 8.3 log 1 o EIDs0 ml-1. CNo fever was shown, d T, turbinates; L, lungs; 1 +, minor changes; 
4+, major changes 
Table 11 AA-CR48 genotype A / W a s h i n g t o n / 8 9 7 / 8 0 / W T  x A / A A / 6 / 6 0 ,  'donor line' 
Virus RNA a protein 1 2 3 4 5 6 7 8 
P2 P3 P1 HA NA NP M NS 
A / A A / 6 / 6 0  A c A A A A A A A 
A / W a s h / 8 4 7 / 8 0  W d W W W W W W W 
CR48 
cl 1 -1 -3PI  W A W W W W A W 
cl 2 - 1 - 3  PI W A W W W W A W 
cl 3 - 1 - 3  PI A A A W W A A W 
cl 4 - 1 - 3  PI A A A W W A A A (vaccine 
line) 
aNumbers refer to migration o} RNA segments on a mized 0.6% agarose--3.0% polyacrylamide gel made with TBE buffer, pH 8.3 run at 37°C 
and 30°C for 30 and 18 h, respectively, bp1, P2, and P3 refer to the order of migration of the polymerase proteins on high resolution Laemmli 
gels (7% acrylamide separation gel). CA represents genes derived from A / A A / 6 / 6 0 .  d w  represents genes derived from the wi ld-type parent, 
A / W a s h i n g t o n / 8 9 7 / 8 0  
the basis for the establishment of the biological and 
biochemical criteria for the use of cold reassortants as 
candidates for live influenza virus vaccines. The data 
presented in Table 10 provide a summary of the cold 
reassortants derived in this laboratory with the 6/2 gene 
configuration that have been documented as being ca and 
ts, and are genetically stable showing no evidence of 
reversion to wt characteristics and no manifestations ofwt 
clinical symptoms when administered intranasally to 
ferrets 51. 
The production and characterization of AA-CR48- 
H3N2 followed the procedures outlined in the flow 
diagram shown in Figure 3, and will be used as a typical 
example of the production of a vaccine candidate. The 
wild type virus, A/Wash/897/80 (H3N2) was cloned at 
39°C in primary bovine kidney cells by Dr Brian Murphy 
(NIAID), and found to be virulent when given to human 
volunteers. The gene constellations of selected clones are 
shown in Table 11. Clone 4 was chosen as the vaccine 
candidate on the basis of its 6/2 gene constellation. The 
AA-CR48 (H3N2) vaccine line was evaluated for 
virulence in animals. Ferrets were used at four months 
old and were screened for the presence of pre-existing 
antibody to the influenza virus being administered. They 
were found to be seronegative prior to use. They were 
inoculated intranasally using a high dose of CR48 clone4, 
with parallel sets of animals used for infection with parent 
strains. Results shown in Table 12 represent the data for 
two lots of the AA-CR48 (H3N2) clone 4 produced and 
safety-tested by Dr Louis Potash (Flow Laboratories, 
McLean, VA) when administered to immunologically 
naive ferrets and compared to the two parental strains. It is 
evident that the cold reassortant line was attenuated and 
acceptable for use as live virus vaccine in man. Recent 
studies in seronegative human voluntee? 3,54 confirmed 
and extended prior studies that demonstrated that the CR 
vaccine lines with 6/2 gene constellation, were not 
reactogenic in adults, were genetically stable, antigenic, 
and were found to induce better resistance than in- 
activated vaccine to experimental challenge. The cold 
reassortants with the 6/2 gene constellation were also 
tested in young seronegative children and were found to 
induce humoral and cellular immune responses, to be 
attenuated, to be genetically stable and to confer signi- 
ficant protection as evaluated by serologic evidence of 
protection55,56. 
As stated above, the transfer of the ca property was 
always performed at 25°C. It has also been shown that the 
"cold" genes of the master strain can be transferred at the 
permissive (33°C) and the non-permissive (38°C) tem- 
peratures, with the retention of both ca and ts markers s7'5~. 
The clones isolated at either temperature were also found 
to be attenuated in ferrets. Thus, the ca property of the cold 
mutant is a stable property which can be transferred 
regardless of the temperature used during reassortment. 
Recently we isolated some limited gene reassortants of 
A/AA/6/60 (H2N2) X A/Alaska/6/77 (H3N2) viruses and 
demonstrated that the ca property can be segregated from 
the ts property at either 25 or 33°C 39. Analysis of these 
clones was performed to explore the functions of both the 
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Table 14 Behaviour of cold reassortants with varying gene composition 
Cold Reassortant (wt-parent) VVT-derived gene Ferret response Reversion Behaviour in man 
AA-CR18-H3N2 HA, NA, NS Reactogenicity at >8.3 logs Yes Same as in ferrets 
(A /Sco t /840 /74)  infectious dose 
AA-CR22-H3Nw HA, NA, Pbl Mild reaction at >8.3 logs No Attenuated 
(A/Victor ia/3/75)  infectious dose 
AA-CR22-H3N2 HA, NA, Pbl (same as above) No Attenuated 
(A/Victor ia/3/75)  
AA-CR31 -H3 N2 HA, NA, M Attenuated ts+, ca Attenuated 
Clone 3 
Clone 10 HA, NA, NS Attenuated No Attenuated 
(A/Alaska/6/77) 
AA-CR48-H3N2 HA, NA, Pbl Mild fever ts÷, ca Attenuated 
Clone 2 Pb2 NP, NS 
(A/Wash/897/80)  
ca and ts properties with respect to virulence in animals. 
Data suggested that limited viral replication in mouse 
lungs was related to the increasing number  of ca genes 
transferred from the master strain to the reassortants. The 
findings also imply that the ca characteristics of A/AA/6/ 
60 donor virus play a supporting role to its ts 
characteristics in alteration of virulence in the cold 
reassortants 59. In addition, studies in ferrets using these 
same reassortants with the "limited' gene composition 
showed the same correlation between a decrease of 
virulence with the increasing number of A/AA/6/60 genes 
present in the cold reassortant. The data in Table 13 
provide evidence that the two cold reassortants containing 
single A/AA/6/60 genes, either the polymerase (Pa) or the 
neuraminidase (NA) gene, showed little attenuation in 
ferrets from the vet parent. However, the cold reassortant 
containing both of these genes showed some decrease in 
virulence compared to the wt parent. Finally, a reassortant 
containing three A/AA/6/60 genes, polymerases (Pbl ,  Pa) 
and NA, was ca and ts, and had an attenuation in ferrets 
equal to that of the cold-adapted parent, A/AA/6/60. 
Examination of clones of differing gene composition 
established that correlation does exist between the 
gene(s) derived from the wt virus, and the reactogenicity of 
the cold reassortants as shown in Table 14 s°,S1, Although 
all the clones tested were definitely attenuated when 
compared to the wt virus, reversion to ts + and some 
reactogenicity were noted at doses > 108'3 EIDs0 ml -l .  In 
addition, infection of ferrets with lines showing reversion 
to ts + but retention of the ca marker did not show any loss 
of their previous attenuation. Results of trials in human 
volunteers using AA-CR31, clones 3 and 1036 showed that 
the two lines were infectious and attenuated, and 
demonstrated that the matrix (M) and non-structural (NS) 
genes were not the major determinants of attenuation 6~'62. 
Correlation of gene composit ion to attenuation has also 
been explored by Ghendon  etaL 63 using cold-adapted and 
virulent strains developed in the USSR. Their conclusion 
also fits the concept that the more genes transferred from 
the ca donor virus to the reassortanl, the more stable its 
attenuated phenotype will be. 
Efforts to link the ca and ts phenotypes of A/AA/6/60 
cold variant virus to specific genes has met with only 
limited success for a number  of reasons. Until recently 
there have been a limited number  of reassortants with 
different gene constellation and none with only single 
genes from A/AA/6/60. In addition, studies have indicated 
that both ca and ts phenotypes are complex in nature, 
involving more than a single gene each 37,39. The genes 
needed to confer the ts phenotype varied depending upon 
the wt parent use@ 7,64. Work is proceeding in this 
laboratory to generate a library of reassortants with a wide 
range of different gene constellations in an attempt to 
generate better evidence for the correlation of ca, ts, and 
attenuated phenotype to specific genotypes in the cold 
reassortants. 
For the present and from a practical consideration, it 
can be stated that cold reassortants with the two wt genes 
coding for the two surface glycoprotein genes and the 
remaining six genes from the cold-adapted parent will be 
best suited as live virus vaccines to be used in man. 
Studies in the development of cold reassortants of 
influenza type B viruses are being pursued along the same 
lines used to develop cold reassortants of type A influenza 
viruses. Ea, rlier in this chapter we have stated that a type B 
ca strain, B/AA/1/66 of proven attenuation in ferrets and 
man 4° has been designated as the ca donor line "master 
strain" for the production of type B influenza reassortants. 
Table 15 summarizes the type B influenza cold adapted 
mutants and the cold reassortant derived by reassortment 
at 25°C in PCK cells. The cold reassortants when tested in 
human volunteers s2,65 in various geographic areas were 
found to be attenuated, had ca and ts markers, and gave no 
evidence of transmission to contacts. The immuno- 
Table 15 The candidate vaccine lines of type B influenza virus 
administered to human volunteers 
Virus line Derivation Testing in man Immuno- 
genicity ~ 
B / A A / 1 / 6 6  CV, Stepwise 
Master Strain 
EVTec/1/69 CV, Stepwise 
AA-CR7 Reassortant 
( B / H K / 8 /  
73 xB/AA/66)  
AA-CR 17 Reassortant 
(B /AA/1 /  
74xB/AA/66)  
RB-77-SFI Reassortant 
( B/Tec/1 O/ 
77xB/AA/66) 
Common Cold High 
Unit-England 
NAMRU-4 Moderate 





aAs evaluated by seroconversion rate and clinical manifestations. 
High = <75% seroconversion. Moderate = 50-75%. Low = <50% 
<50% 
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genicity of these cold reassortants ranged from low (50%) 
seroconversion after immunizat ion with AA-CR17 type B 
reassortant, through moderate (~60%) seroconversion, to 
high ("-75%) seroconversion after the administration of 
AA-CR7 type B reassortant. The work with influenza type 
B cold reassortants is embryonic. Electrophoretic 
methods of genotyping the parental origin of all eight 
RNA segments is available and similar to that used for 
type A viruses. Definite protein-gene assignments are in 
progress, and will be completed soon. Emphasis  in the 
near future will be to develop and characterize new type B 
cold reassortants for use with type A cold reassortants as 
bivalent live influenza virus vaccine. 
Conclusions 
Viruses of  almost every RNA virus genus and of two 
DNA virus genera have been cold adapted to grow at 
temperatures suboptimal for their normal growth. In 
almost all cases there has been correlation of the 
acquisition in these viruses of temperature sensitivity in 
tissue culture, and attenuation in the normal host: animal 
or man. In only a few instances did this correlation break 
down, see Rhabdovirus genus, above. Even in this genus 
there are conflicting reports, and the resolution may lie in 
the manner  in which the cold adaptation was performed 
and the strain of virus used. The most successful method 
of cold adaptation for developing a live virus vaccine line 
appears to be a stepwise lowering of the incubation 
temperature, allowing time for multiple cold-adapted 
lesions to occur and/or be selected for in the viral genome. 
Plaque-purification and screening of virus for desired 
traits at different stages of the stepwise adaptation is the 
most efficient way to achieve the desired strain. If the 
starting virus is a recent isolate which has not already 
been extensively adapted to a particular host cell system 
the cold adaptation process appears to proceed more 
easily and with better and more consistent results. In most 
cases the adaptation process is performed in tissue culture 
in a heterologous host from the viruses' normal host in 
nature. Thus, while the virus is being cold-adapted it may 
also be host-adapted. This adaptation may complicate the 
linkage of attenuation to specific cold adapted genes, but 
practically it may be an asset in the production of a stable, 
attenuated virus variant. Finally, for many virus diseases, 
cold adaptation can provide suitable live virus vaccine 
candidates capable of providing safe, efficient protection 
from wild type virus challenge. 
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